Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

POINT Biopharma Global Inc. (PNT)

6.7   -0.16 (-2.33%) 11-25 13:00
Open: 6.83 Pre. Close: 6.86
High: 6.94 Low: 6.66
Volume: 282,633 Market Cap: 708(M)

Technical analysis

as of: 2022-11-25 1:59:39 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 9.58     One year: 11.46
Support: Support1: 5.59    Support2: 4.65
Resistance: Resistance1: 8.2    Resistance2: 9.81
Pivot: 7.34
Moving Average: MA(5): 6.69     MA(20): 7.76
MA(100): 8.26     MA(250): 7.42
MACD: MACD(12,26): -0.5     Signal(9): -0.4
Stochastic oscillator: %K(14,3): 31.2     %D(3): 28.8
RSI: RSI(14): 41.2
52-week: High: 10.97  Low: 4.25
Average Vol(K): 3-Month: 946 (K)  10-Days: 1,735 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ PNT ] has closed above bottom band by 36.8%. Bollinger Bands are 96.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.97 - 7 7 - 7.02
Low: 6.61 - 6.65 6.65 - 6.68
Close: 6.79 - 6.86 6.86 - 6.91

Company Description

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.

Headline News

Fri, 25 Nov 2022
Success of LEO PNT constellation at ESA ministerial means EU likely to add LEO complement to Galileo - Space Intel Report

Wed, 23 Nov 2022
POINT Biopharma Global Inc. (NASDAQ:PNT) Director Purchases $11217.60 in Stock - MarketBeat

Tue, 22 Nov 2022
Providing essential and assured PNT to every tactical vehicle is ACĀ²ES (aces) - Breaking Defense

Fri, 18 Nov 2022
NextNav Combining Technologies to Create Near Nationwide Resilient PNT Capabilities - Inside GNSS

Thu, 17 Nov 2022
Pacific Defense Awarded Defense Innovation Unit Contract to Deliver Assured PNT 3U Cards for Army and Broader DoD adoption - Business Wire

Mon, 14 Nov 2022
POINT Biopharma (PNT) Stock Plummets Over 35%: Details - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 106 (M)
Shares Float 79 (M)
% Held by Insiders 15.2 (%)
% Held by Institutions 57.8 (%)
Shares Short 7,180 (K)
Shares Short P.Month 7,380 (K)

Stock Financials

EPS -0.69
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.97
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -16.6
Return on Equity (ttm) -27.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -65 (M)
Levered Free Cash Flow -49 (M)

Stock Valuations

PE Ratio -9.72
PEG Ratio 0
Price to Book value 2.25
Price to Sales 0
Price to Cash Flow -10.91

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.